• Seung Eun Lee, Kyung Sik Kim, Wan Bae Kim, In-Gyu Kim, Yang Won Nah, Dong Hee Ryu, Joon Seong Park, Myung Hee Yoon, Jai Young Cho, Tae Ho Hong, Dae Wook Hwang, Dong Wook Choi, and Korean Association of Hepato-Biliary and Pancreas Surgery.
• Department of Surgery, Chung-Ang University College of Medicine, Seoul, Korea.
• J. Korean Med. Sci. 2014 Oct 1; 29 (10): 133313401333-40.

AbstractAt present, surgical treatment is the only curative option for gallbladder (GB) cancer. Many efforts therefore have been made to improve resectability and the survival rate. However, GB cancer has a low incidence, and no randomized, controlled trials have been conducted to establish the optimal treatment modalities. The present guidelines include recent recommendations based on current understanding and highlight controversial issues that require further research. For T1a GB cancer, the optimal treatment modality is simple cholecystectomy, which can be carried out as either a laparotomy or a laparoscopic surgery. For T1b GB cancer, either simple or an extended cholecystectomy is appropriate. An extended cholecystectomy is generally recommended for patients with GB cancer at stage T2 or above. In extended cholecystectomy, a wedge resection of the GB bed or a segmentectomy IVb/V can be performed and the optimal extent of lymph node dissection should include the cystic duct lymph node, the common bile duct lymph node, the lymph nodes around the hepatoduodenal ligament (the hepatic artery and portal vein lymph nodes), and the posterior superior pancreaticoduodenal lymph node. Depending on patient status and disease severity, surgeons may decide to perform palliative surgeries.

25 keywords...

hide…